In vitro clearance of dexmedetomidine in extracorporeal membrane oxygenation

Perfusion (United Kingdom)

Volumn 28, Issue 1, 2013, Pages 40-46

  Wagner, D ^a   Pasko, D ^a   Phillips, K ^b   Waldvogel, J ^a   Annich, G ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

clearance; dexmedetomidine; extracorporeal membrane oxygenation; in vitro; sedation

Indexed keywords

DEXMEDETOMIDINE; POLYVINYLCHLORIDE;

ARTICLE; CONCENTRATION (PARAMETERS); DRUG ABSORPTION; DRUG CLEARANCE; EXTRACORPOREAL OXYGENATION; IN VITRO STUDY; OXYGENATOR; PRIORITY JOURNAL;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; DEXMEDETOMIDINE; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; TIME FACTORS;

EID: 84871595605     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659112456894     Document Type: Article

References (41)

1. Bartlett RH, Roloff DW, Cornell RG, Andrews AF, Dillon PW, Zwischenberger JB. Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. Pediatrics. 1985 ; 76: 479-487
2. Caron E, Maguire DP. Current management of pain, sedation, and narcotic physical dependency of the infant on ECMO. J Perinat Neonatal Nurs. 1990 ; 4: 63-74
3. Okamoto MP, Kawaguchi DL, Amin AN. Evaluation of propofol infusion syndrome in pediatric intensive care. Am J Health-System Pharmacy. 2003 ; 60: 2007-2014
4. Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000 ; 59: 263 269-268 270
5. Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol. 1988 ; 150: 9-14
6. Levanen J, Makela ML, Scheinin H. Dexmedetomidine premedication attenuates ketamine-induced cardiostimulatory effects and postanesthetic delirium. Anesthesiology. 1995 ; 82: 1117-1125
7. Tobias JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatr Crit Care Med. 2007 ; 8: 115-131
8. Petroz GC, Sikich N, James M, et al. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. Anesthesiology. 2006 ; 105: 1098-1110
9. Potts AL, Anderson BJ, Warman GR, Lerman J, Diaz SM, Vilo S. Dexmedetomidine pharmacokinetics in pediatric intensive care - a pooled analysis. Paediatr Anaesth. 2009 ; 19: 1119-1129
10. Chrysostomou C, Di Filippo S, Manrique AM, et al. Use of dexmedetomidine in children after cardiac and thoracic surgery.[see comment]. Pediatric Critical Care Medicine. 2006 ; 7: 126-131
11. Berkenbosch JW, Wankum PC, Tobias JD. Prospective evaluation of dexmedetomidine for noninvasive procedural sedation in children.[see comment]. Pediatric Critical Care Medicine. 2005 ; 6: 435-439
12. Tobias JD, Berkenbosch JW. Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam. Southern Medical Journal. 2004 ; 97: 451-455
13. Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: a novel sedative-analgesic agent. BUMC Proceedings. 2001 ; 14: 13-21
14. Czaja AS, Zimmerman JJ. The use of dexmedetomidine in critically ill children. Pediatr Crit Care Med. 2009 ; 10: 381-386
15. Wong J, Steil GM, Curtis M, Papas A, Zurakowski D, Mason KP. Cardiovascular effects of dexmedetomidine sedation in children. Anesth Analg. 2012 ; 114: 193-199
16. Ji QC, Zhou JY, Gonzales RJ, Gage EM, El-Shourbagy TA. Simultaneous quantitation of dexmedetomidine and glucuronide metabolites (G-Dex-1 and G-Dex-2) in human plasma utilizing liquid chromatography with tandem mass spectrometric detection. Rapid Communications in Mass Spectrometry. 2004 ; 18: 1753-1760
17. Lee JI, Su F, Shi H, Zuppa AF. Sensitive and specific liquid chromatography-tandem mass spectrometric method for the quantitation of dexmedetomidine in pediatric plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 ; 852: 195-201
18. Mulla H, Lawson G, von Anrep C, et al. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion. 2000 ; 15: 21-26
19. Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit. 1993 ; 15: 263-266
20. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet. 2003 ; 42: 403-417
21. Suzuki T, Uchida I, Mashimo T. Sorptive loss of volatile and gaseous anesthetics from in vitro drug application systems. Anesth Analg. 2005 ; 100: 427-430
22. Mulla H, Lawson G, Woodland ED, et al. Effects of neonatal extracorporeal membrane oxygenation circuits on drug disposition. Current Therapeutic Research. 2000 ; 61: 838-848
23. Burda G and, Trittenwein G. Issues of pharmacology in pediatric cardiac extracorporeal membrane oxygenation with special reference to analgesia and sedation. Artif Organs. 1999 ; 23: 1015-1019
24. Noerr B. ECMO and pharmacotherapy. Neonatal Netw. 1996 ; 15: 23-31
25. Dagan O, Klein J, Bohn D, Koren G. Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit Care Med. 1994 ; 22: 1099-1101
26. Mulla H, McCormack P, Lawson G, Firmin RK, Upton DR. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology. 2003 ; 99: 275-282
27. Bhatt-Meht V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. Perfusion. 2005 ; 20: 309-315
28. Geiduschek JM, Lynn AM, Bratton SL, et al. Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation. Crit Care Med. 1997 ; 25: 360-364
29. Thiara A.P., Hoel TN, Kristiansen F, Karlsen HM, Fiane AE, Svennevig JL. Evaluation of oxygenators and centrifugal pumps for long-term pediatric extracorporeal membrane oxygenation. Perfusion. 2007 ; 22: 323-326
30. Yliruusi JK, Uotila JA, Kristoffersson ER. Effect of flow rate and type of i.v. container on adsorption of diazepam to i.v. administration systems. Am J Hosp Pharm. 1986 ; 43: 2795-2799
31. Tarvainen T, Svarfvar B, Akerman S, et al. Drug release from a porous ion-exchange membrane in vitro. Biomaterials. 1999 ; 20: 2177-2183
32. Li W, Zhang Z, Wu L, Tian Y, Feng S, Chen Y. Determination of dexmedetomidine in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: application to a pharmacokinetic study. J Pharm Biomed Anal. 2009 ; 50: 897-904
33. Arnold JH, Truog RD, Orav EJ, Scavone JM, Hershenson MB. Tolerance and dependence in neonates sedated with fentanyl during extracorporeal membrane oxygenation. Anesthesiology. 1990 ; 73: 1136-1140
34. Tobias JD, Berkenbosch JW. Initial experience with dexmedetomidine in paediatric-aged patients. Paediatr Anaesth. 2002 ; 12: 171-175
35. Preston TJ, Hodge AB, Riley JB, Leib-Sargel C, Nicol KK. In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit. J Extra Corpor Technol. 2007 ; 39: 234-237
36. Wildschut ED, Ahsman MJ, Allegaert K, Mathot RA, Tibboel D. Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010 ; 36: 2109-2116
37. Smith AH, Hardison DC, Worden CR, Fleming GM, Taylor MB. Acute renal failure during extracorporeal support in the pediatric cardiac patient. ASAIO J. 2009 ; 55: 412-416
38. Swaniker F, Bartlett R. Incidence and outcome of renal failure in adult ECMO patients. ASAIO. 2001 ; 47: 145
39. Wildschut ED, Ahsman MJ, Houmes RJ, et al. Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation (ECMO). Curr Drug Metab. 2012 ; 13: 767-777
40. Varghese JM, Roberts JA, Lipman J. Pharmacokinetics and pharmacodynamics in critically ill patients. Curr Opin Anaesthesiol. 2010 ; 23: 472-478
41. Anderson GD, Lynn AM. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy. 2009 ; 29: 680-690